Paladin Labs Inc. (PLB.TO: Quote) said Health Canada has approved Oralair. Oralair is a sublingual grass pollen immunotherapy tablet for the treatment of the symptoms of moderate to severe seasonal grass pollen allergic rhinitis with or without conjunctivitis.
"We are pleased and excited that Health Canada has granted regulatory approval for Oralair™", said Mark Beaudet, interim President and Chief Executive Officer of Paladin Labs Inc. "We anticipate launching Oralair™ in time for the 2013 allergy season and are confident that, when launched, Oralair™ will provide Canadian allergy sufferers with a safe, effective and convenient alternative for the treatment of seasonal grass allergies."
Oralair has been marketed in Europe since 2008 and is now approved in 27 countries. Paladin obtained the Canadian development, promotion and distribution rights for Oralair for grass allergies, hdm tablet for dust mites allergies and Stalair rBet v 1 tablet for birch pollen allergies from Stallergenes SA.
Click here to receive FREE breaking news email alerts for Paladin Labs Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com